Trial Profile
A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Tazarotene (Primary)
- Indications Acne vulgaris
- Focus Pharmacokinetics
- Sponsors Stiefel Laboratories
- 07 Apr 2014 New trial record
- 21 Apr 2010